(Press-News.org)
The investigational drug elinzanetant significantly reduces hot flashes and night sweats for post-menopausal women, a large, international clinical trial has found.
The OASIS-3 trial enrolled more than 600 postmenopausal women, ages 40 to 65, at 83 sites in North America and Europe. Participants were given either 120 mg of elinzanetant or a harmless placebo daily for 52 weeks.
Elinzanetant recipients saw a more than 73% reduction in the frequency and severity of “vasomotor symptoms” – hot flashes and night sweats – by week 12, the researchers report. The trial also found secondary benefits such as a reduction in sleep disturbances and overall improvements in reported quality of life, though the study did not have sufficient scope to assess these secondary benefits fully.
The drug had no harmful effects on the liver or bone density, the researchers determined.
“Elinzanetant, the first dual neurokinin-1 and 3 receptor antagonist to complete Phase 3 testing, has shown promising results. This yearlong study not only confirmed the initial findings of rapid and significant reduction in the frequency and severity of hot flashes and night sweats but also provided evidence that these effects were sustained over a year, offering hope for longer-term relief,” said researcher JoAnn V. Pinkerton, MD, UVA Health’s director of midlife health and emeritus executive director of the North American Menopause Society. “For those dealing with moderate to severe VMS due to menopause, the treatment options have been limited, especially for those who cannot or choose not to undergo hormone therapy. The disruptive nature of these bothersome hot flashes, particularly when they are more severe, can significantly affect women’s daily lives, both at work and at home, underscoring the urgent need for effective non-hormonal treatments.”
About Elinzanetant
Hot flashes are caused by decreased estrogen levels during menopause and, for some women, years after. Hormone therapy can replace estrogen, but this can come with side effects such as breast tenderness, bloating, headaches and spotting. Less commonly, long-term hormone therapy can cause strokes or increase the risk of certain cancers. Women also may be unable to take the treatment because they have a history of certain medical conditions, such as blood clots or cancer.
Elinzanetant, on the other hand, is a nonhormonal drug that contains no estrogen, so it could offer an important new option for women who cannot or do not wish to receive existing treatment options.
The drug had shown promise in the previous OASIS-1 and -2 clinical trials, but OASIS-3 put elinzanetant to the test at a much larger scale and for an entire year. “Outcomes from this 52-week study were consistent with those observed in the 26-week OASIS-1 and OASIS-2 trials, contributing to the robustness of the findings and indicating the sustained benefit and safety of elinzanetant in a broad population with VMS [vasomotor symptoms] over a prolonged duration of use,” the researchers write in a new scientific paper outlining their findings.
The drug’s most commonly reported side effects were sleepiness, fatigue and headache. The researchers also looked at mammograms and measures such as endometrial thickness for potential safety concerns but found none.
“In the OASIS-4 trial of postmenopausal women with bothersome hot flashes on endocrine therapy for breast cancer, similar results were found with elinzanetant providing safe, effective relief of hot flashes,” Pinkerton said. “What is so exciting is that with elinzanetant, we potentially have a new treatment option that can be used first-line for moderate to severe hot flashes whether due to menopause or breast cancer endocrine therapy.”
The federal Food and Drug Administration would need to approve elinzanetant before it could become available for patients. The agency delayed a decision on the drug in July, telling the drug’s maker, Bayer, that it needed more time to review the company’s application, which included data from the OASIS-3 trial.
Findings Published
Pinkerton and her co-authors have published the OASIS-3 results in JAMA Internal Medicine. The article is open access, meaning it is free to read.
A full list of the authors and their disclosures is included in the paper. The trial was funded by Bayer.
To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.
END
“[…]we have identified FGF21 as a novel biomarker in ALS that is detected in multiple compartments including muscle, spinal cord, and circulation.”
BUFFALO, NY — September 18, 2025 — A new research paper was published in Volume 17, Issue 8 of Aging-US on August 9, 2025, titled “The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity.”
In this study, led by first author Abhishek Guha and corresponding author Peter H. King from the University ...
Music therapy could significantly reduce heart rate, blood pressure and patient–ventilator asynchronies for patients admitted to the cardiac intensive care unit (ICU), according to research being presented at ACC Latin America 2025 taking place September 18-20 in Mexico City.
Music therapy is the use of music and its elements to reduce stress and improve quality of life. A music therapist uses music therapy as a non-pharmacological and non-invasive intervention to improve a patient's physical, social, communicative, emotional, intellectual, and spiritual ...
Despite improved statin use and cholesterol control, cardiovascular disease risk rose in Mexico between 2016 and 2023, according to a study being presented at ACC Latin America 2025 that used region-specific tools to more accurately predict the local disease burden.
Cardiovascular disease is the leading cause of death in the world, costing billions each year in care. Factors such as socioeconomics, demographics, hypertension, cholesterol, air pollution, obesity and more can play a role in the types of cardiovascular disease (CVD) burden a country or region may be most impacted by. Most models to predict cardiovascular disease risk use data ...
WASHINGTON — Researchers have developed a flexible optical touch sensor that can simultaneously detect the strength and location of pressure with high sensitivity and stability. The advance in tactile sensing paves the way for next-generation robotic touch interfaces, advanced medical diagnostics and highly responsive wearable electronics.
“Unlike conventional optical tactile sensors, which tend to have a single input-output path, our sensor design achieves multiple optical channels by embedding polymer ...
Achalasia is a disease caused by impaired movement of the esophagus. Patients experience food getting stuck and regurgitated, as well as chest pain. Currently, upper gastrointestinal endoscopy and high-resolution manometry are commonly used for diagnosis; however, these techniques are invasive.
Achalasia has some distinct features that are visible on plain chest X-ray such as twisting or dilation of the esophagus, and fluid retention. However, these signs are vague in most cases, and for this reason, X-rays normally require swallowing barium to diagnose the condition.
A research group from Osaka Metropolitan University ...
Global warming poses a growing threat to human health and work performance. Currently, about 3.6 billion people worldwide live in areas highly susceptible to climate change. From 2000 to 2019, more than 480,000 heat-related deaths occurred globally each year. Extreme heat also impairs focus and productivity and worsens mood by elevating stress hormones and disrupting sleep. In response to the increasing frequency of heat waves, The Hong Kong Polytechnic University (PolyU) scholars are developing next-generation personal cooling solutions that push the limits of conventional clothing and promote ...
A multi-institutional team led by Weill Cornell Medicine investigators has been awarded a five-year, $20.8 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for advanced preclinical development of a promising experimental HIV vaccine.
A successful vaccine to prevent new HIV infections would be a major public health breakthrough. About 1.3 million people acquired HIV in 2024, according to the World Health Organization, and at the end of that year an estimated 41 million people were living with the ...
Women suffering from long COVID have a greater risk1 of experiencing abnormal uterine bleeding2. The symptoms of the illness intensify during the perimenstrual and proliferative phases of the menstrual cycle, notably fatigue, headaches, and muscle pain. This bidirectional relationship between long COVID and menstrual disorders has been revealed by a French-British research team co-led by a CNRS researcher3. An inflammatory reaction is suspected of being behind this connection, after the discovery of an immune cell cluster in the endometrium of the patients receiving treatment. ...
In global terms, the past year was distinguished not only by extreme drought but also by unusually heavy rainfall. These are the core findings of the report of the World Meteorological Organization (WMO) on the status of our planet's water resources that was published today. The regions most affected by severe drought conditions in 2024 were the Amazon basin and Southern Africa. There was excessive rainfall, for instance, in the African tropics and the resultant flooding resulted in the deaths of 2500 people while 4 million were forced from their homes. ...
A research group from the National Cancer Research Centre (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult.
The mutation prevents telomeres, the structures that protect chromosomes, from repairing.
According to the authors, understanding the effect of mutations like this “is critical to developing personalised therapies” against ‘telomere syndromes’, a group of diseases that includes pulmonary fibrosis and several cancer types.
Idiopathic pulmonary fibrosis is a potentially fatal disease currently without treatment, in which lung tissue develops scarring ...
